RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-1.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.75B
AUM Growth
-$879M
(-33%)
Cap. Flow
-$729M
Cap. Flow
% of AUM
-41.7%
Top 10 Holdings %
Top 10 Hldgs %
36.57%
Holding
113
New
6
Increased
25
Reduced
47
Closed
16
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$12.5M |
| 2 |
Danaher
DHR
|
$12.1M |
| 3 |
Evolent Health
EVH
|
$6.02M |
| 4 |
Mineralys Therapeutics
MLYS
|
$5.09M |
| 5 |
Merus
MRUS
|
$3.71M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
$56.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
$48.8M |
| 3 |
Freshpet
FRPT
|
$48.5M |
| 4 |
UnitedHealth
UNH
|
$39.5M |
| 5 |
Travere Therapeutics
TVTX
|
$36.8M |
Sector Composition
| 1 | Healthcare | 99.7% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
iRhythm Technologies
IRTC
$5.82B
| $26.6M | 1.52% |
254,300
-143,200
| -36% | -$15M |
|
|
27
Evolent Health
EVH
$1.11B
| $25.5M | 1.46% |
2,695,700
+635,700
| +31% | +$6.02M |
|
28
Scholar Rock
SRRK
$3.02B
| $24.5M | 1.4% |
761,541
+44,759
| +6% | +$1.44M |
|
29
Kymera Therapeutics
KYMR
$3.11B
| $21.7M | 1.24% |
794,437
-239,700
| -23% | -$6.56M |
|
30
Exact Sciences
EXAS
$10.2B
| $20.8M | 1.19% |
480,000
+30,000
| +7% | +$1.3M |
|
31
Acadia Healthcare
ACHC
$2.19B
| $20.7M | 1.18% |
681,100
+97,600
| +17% | +$2.96M |
|
32
Structure Therapeutics
GPCR
$1.27B
| $19.6M | 1.12% |
1,132,979
+52,016
| +5% | +$900K |
|
33
Summit Therapeutics
SMMT
$19.3B
| $19.2M | 1.1% |
995,000
-59,000
| -6% | -$1.14M |
|
34
Edwards Lifesciences
EW
$47.5B
| $18.5M | 1.06% |
255,000
-290,000
| -53% | -$21M |
|
|
35
Tarsus Pharmaceuticals
TARS
$2.43B
| $18.2M | 1.04% |
354,376
+243,487
| +220% | +$12.5M |
|
36
Tenet Healthcare
THC
$17.3B
| $17.5M | 1% |
130,000
+800
| +0.6% | +$108K |
|
37
Legend Biotech
LEGN
$6.66B
| $17.4M | 1% |
512,932
+800
| +0.2% | +$27.1K |
|
38
Immunovant
IMVT
$2.99B
| $16.7M | 0.95% |
975,803
+66,700
| +7% | +$1.14M |
|
39
Azenta
AZTA
$1.39B
| $16.5M | 0.94% |
475,000
| – | – |
|
40
Inspire Medical Systems
INSP
$2.56B
| $15.8M | 0.9% |
99,250
-30,750
| -24% | -$4.9M |
|
41
Amicus Therapeutics
FOLD
$2.46B
| $15.6M | 0.89% |
1,909,362
-690,063
| -27% | -$5.63M |
|
42
Warby Parker
WRBY
$3.17B
| $15.2M | 0.87% |
835,000
-85,000
| -9% | -$1.55M |
|
|
MREO
43
Mereo BioPharma
MREO
$282M
| $15M | 0.86% |
6,684,247
-2,914,923
| -30% | -$6.56M |
|
44
Celldex Therapeutics
CLDX
$1.52B
| $14.7M | 0.84% |
812,653
-409,529
| -34% | -$7.43M |
|
45
Oscar Health
OSCR
$5.02B
| $13.8M | 0.79% |
1,050,000
| – | – |
|
46
West Pharmaceutical
WST
$18B
| $13.5M | 0.77% |
60,250
-108,500
| -64% | -$24.3M |
|
47
Vera Therapeutics
VERA
$1.54B
| $12.5M | 0.72% |
520,796
+32,933
| +7% | +$791K |
|
|
48
Danaher
DHR
$143B
| $12.1M | 0.69% |
+58,800
| New | +$12.1M |
|
49
NewAmsterdam Pharma
NAMS
$3.04B
| $11M | 0.63% |
536,111
-231,411
| -30% | -$4.74M |
|
50
Sarepta Therapeutics
SRPT
$1.96B
| $10.2M | 0.58% |
159,300
-148,200
| -48% | -$9.46M |
|